CA3242280A1 - Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody - Google Patents

Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody

Info

Publication number
CA3242280A1
CA3242280A1 CA3242280A CA3242280A CA3242280A1 CA 3242280 A1 CA3242280 A1 CA 3242280A1 CA 3242280 A CA3242280 A CA 3242280A CA 3242280 A CA3242280 A CA 3242280A CA 3242280 A1 CA3242280 A1 CA 3242280A1
Authority
CA
Canada
Prior art keywords
antibody
methods
amyloid beta
tau
beta protofibril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242280A
Other languages
English (en)
French (fr)
Inventor
Larisa Reyderman
Jin Zhou
Lynn Kramer
Michael Irizarry
Pallavi SACHDEV
Shobha DHADDA
David Li
Kristin WILDSMITH
Pau ACEVES BALDO
Sumit RAWAL
Akihiko Koyama
Chad SWANSON
Michio KANEKIYO
June Kaplow
David Verbel
Ishani LANDRY
Seiichi HAYATO
Robert Gordon
Randall Bateman
Eric MCDADE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Washington University in St Louis WUSTL
Original Assignee
Eisai R&D Management Co Ltd
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2021/000937 external-priority patent/WO2023111618A1/en
Application filed by Eisai R&D Management Co Ltd, Washington University in St Louis WUSTL filed Critical Eisai R&D Management Co Ltd
Publication of CA3242280A1 publication Critical patent/CA3242280A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nuclear Medicine (AREA)
CA3242280A 2021-12-17 2022-11-08 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody Pending CA3242280A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163291315P 2021-12-17 2021-12-17
US63/291,315 2021-12-17
IBPCT/IB2021/000937 2021-12-17
PCT/IB2021/000937 WO2023111618A1 (en) 2021-12-17 2021-12-17 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
PCT/US2022/079509 WO2023114586A1 (en) 2021-12-17 2022-11-08 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody

Publications (1)

Publication Number Publication Date
CA3242280A1 true CA3242280A1 (en) 2023-06-22

Family

ID=84387973

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242280A Pending CA3242280A1 (en) 2021-12-17 2022-11-08 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody

Country Status (8)

Country Link
US (1) US20250051427A1 (https=)
EP (1) EP4448005A1 (https=)
JP (1) JP2024547001A (https=)
KR (1) KR20240115910A (https=)
AU (1) AU2022410770A1 (https=)
CA (1) CA3242280A1 (https=)
MX (1) MX2024007288A (https=)
WO (1) WO2023114586A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025019457A1 (en) 2023-07-15 2025-01-23 Eisai R&D Management Co., Ltd. Antimicrobial peptides
WO2025049938A1 (en) * 2023-08-31 2025-03-06 Florida Atlantic University Board Of Trustees Non-invasive delivery method of antibodies to the brain for treatment of brain diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
US20210324056A1 (en) * 2018-07-24 2021-10-21 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
CN112187401B (zh) 2019-07-03 2022-06-14 华为技术有限公司 多时间单元传输方法及相关装置
US11877315B2 (en) 2020-09-15 2024-01-16 Qualcomm Incorporated Wireless device digital beamforming capability indication

Also Published As

Publication number Publication date
KR20240115910A (ko) 2024-07-26
EP4448005A1 (en) 2024-10-23
WO2023114586A1 (en) 2023-06-22
MX2024007288A (es) 2024-06-28
AU2022410770A1 (en) 2024-06-13
JP2024547001A (ja) 2024-12-26
US20250051427A1 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
CA3242280A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
WO2021262910A3 (en) Tubulysins and protein-tubulysin conjugates
WO2020132658A3 (en) Tubulysins and protein-tubulysin conjugates
BR112021019107A2 (pt) Anticorpos contra amiloide-beta piroglutamato e usos dos mesmos
WO2004113277A8 (en) Methods and compositions for treating amyloid-related diseases
WO2023280092A9 (zh) 抗体药物偶联物及其应用
WO2019217145A8 (en) Anti-dll3 antibodies and uses thereof
EP3907223A4 (en) PROCESS FOR PRODUCTION OF DRUG TOXIN PNU-159682 AN ANTIBODY DRUG CONJUGATE AND INTERMEDIATE THEREOF
WO2022034524A3 (en) Antibodies against ilt2 and use thereof
MX2021010453A (es) Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos.
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
MX2022015959A (es) Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MX2024011805A (es) Nuevos anticuerpos anti-fgfr2
BR112019008359A2 (pt) método para tratamento da doença de alzheimer, e, composição farmacêutica.
WO2021226321A3 (en) Anti-tumor associated antigen antibodies and uses thereof
WO2023081194A3 (en) Methods for treating alzheimer's disease
WO2024186859A3 (en) Anti-tl1a antibody compositions and methods of treatment for sarcoidosis
BR112023000455A2 (pt) Tratamento de doença inflamatória que usa anticorpos de fator antitecidual
WO2024173838A3 (en) Anti-tl1a antibody compositions and methods of treatment in the bile duct
WO2024211236A3 (en) Antibody-drug conjugates and uses thereof
WO2021151180A3 (pt) Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas
WO2023016826A3 (en) Method and means for enhancing therapeutic antibodies

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241101

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241101

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241217